Today marks the one-year anniversary of a unique moment in our country’s health care history.

Unfortunately, it is not a celebration: 365 days ago, people living with early Alzheimer’s became the only Americans to be denied access to FDA-approved treatments, thanks to an unprecedented decision made by the Centers for Medicare & Medicaid Services (CMS). One year later, here are 5 important things to know about the impact of this decision and why CMS must immediately reverse it:
 

This is the 1st time in history that Medicare has refused to cover a drug that has been given FDA approval.
 

Each day CMS denies access to FDA-approved Alzheimer’s treatments, more than 2,000 people transition out of eligibility.
 

In the last 365 days, more than 730,000 Americans have been denied access to FDA-approved treatments…and as a result, they have also been denied more time with their loved ones.
 

More than 100 bipartisan members of Congress have actively called on CMS to reverse their decision.
 

People living with Alzheimer’s currently have a 0% survival rate. Now that we have medical breakthroughs, the least we can do is offer those living with Alzheimer’s, a fatal disease, #MoreTime.

Join with the Alzheimer’s Association. Use your voice to change this unjust action — click here.